[{"id":"e4dc24bc-6ed7-4733-b143-e2d056f8bf8d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05921812","created_at":"2023-06-27T14:08:25.821Z","updated_at":"2024-07-02T16:35:26.824Z","phase":"","brief_title":"Biochemical Role of Circulating microRNAs Expression as Diagnostic Markers for Non-Hodgkin's Lymphoma Patients","source_id_and_acronym":"NCT05921812","lead_sponsor":"Sohag University","biomarkers":" MIR155 • MIR21 • MIR16 • MIR16-1","pipe":"","alterations":" ","tags":["MIR155 • MIR21 • MIR16 • MIR16-1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 02/01/2024","start_date":" 02/01/2024","primary_txt":" Primary completion: 05/30/2024","primary_completion_date":" 05/30/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2023-12-07"},{"id":"fe98e2d0-590c-4f9c-b62c-d6aca24eea9b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06015815","created_at":"2023-08-29T16:10:13.927Z","updated_at":"2024-07-02T16:35:38.717Z","phase":"","brief_title":"The Association of MicroRNA21-155 Levels With Acute Side Effects In Patients With Stage III NSCLC With Definitive CRT","source_id_and_acronym":"NCT06015815","lead_sponsor":"Ankara University","biomarkers":" MIR155 • MIR21","pipe":" | ","alterations":" miR-155 expression","tags":["MIR155 • MIR21"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e miR-155 expression"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 10/05/2019","start_date":" 10/05/2019","primary_txt":" Primary completion: 04/29/2020","primary_completion_date":" 04/29/2020","study_txt":" Completion: 08/15/2020","study_completion_date":" 08/15/2020","last_update_posted":"2023-08-29"},{"id":"b297142a-7927-411a-9428-daaa60495dc1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05901376","created_at":"2023-06-13T17:08:02.193Z","updated_at":"2024-07-02T16:35:45.783Z","phase":"","brief_title":"MicroRNAs From Blood Samples as Biomarkers for Gastric Cancer Detection","source_id_and_acronym":"NCT05901376","lead_sponsor":"King Chulalongkorn Memorial Hospital","biomarkers":" MIR21 • MIR199A • MIR223 • MIR106B • MIR20A","pipe":"","alterations":" ","tags":["MIR21 • MIR199A • MIR223 • MIR106B • MIR20A"],"overall_status":"Recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 04/25/2023","start_date":" 04/25/2023","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-06-13"},{"id":"bdc6fc23-157c-455c-84b1-7f3ba467351f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02983279","created_at":"2021-01-18T14:40:35.597Z","updated_at":"2024-07-02T16:35:58.100Z","phase":"","brief_title":"Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast Cancer","source_id_and_acronym":"NCT02983279","lead_sponsor":"Sidney Kimmel Cancer Center at Thomas Jefferson University","biomarkers":" MIR21","pipe":" | ","alterations":" miR-21 expression","tags":["MIR21"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e miR-21 expression"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 09/20/2016","start_date":" 09/20/2016","primary_txt":" Primary completion: 10/27/2021","primary_completion_date":" 10/27/2021","study_txt":" Completion: 12/29/2022","study_completion_date":" 12/29/2022","last_update_posted":"2023-01-06"},{"id":"202a63d1-07ad-43e6-b0e5-90f62602468d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04149613","created_at":"2021-01-18T20:15:40.071Z","updated_at":"2024-07-02T16:36:07.094Z","phase":"","brief_title":"Predictive and Prognostic Value of Inflammatory Markers and microRNA in Stage IV Colorectal Cancer","source_id_and_acronym":"NCT04149613","lead_sponsor":"American University of Beirut Medical Center","biomarkers":" MIR155 • MIR200B • MIR21 • MIR200C • MIR126 • MIR210 • MIR31 • CRP • MIR19A • MIR203A • MIR29A • MIR345","pipe":"","alterations":" ","tags":["MIR155 • MIR200B • MIR21 • MIR200C • MIR126 • MIR210 • MIR31 • CRP • MIR19A • MIR203A • MIR29A • MIR345"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 100","initiation":"Initiation: 05/25/2018","start_date":" 05/25/2018","primary_txt":" Primary completion: 12/18/2023","primary_completion_date":" 12/18/2023","study_txt":" Completion: 04/18/2024","study_completion_date":" 04/18/2024","last_update_posted":"2022-07-20"},{"id":"66b81fc1-813a-4303-b453-56e0526f97da","acronym":"","url":"https://clinicaltrials.gov/study/NCT05449847","created_at":"2022-07-08T14:55:31.243Z","updated_at":"2024-07-02T16:36:07.587Z","phase":"","brief_title":"Plasma MicroRNA for Prediction of Hepatocellular Carcinoma","source_id_and_acronym":"NCT05449847","lead_sponsor":"Benha University","biomarkers":" MIR21","pipe":"","alterations":" ","tags":["MIR21"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 05/13/2021","start_date":" 05/13/2021","primary_txt":" Primary completion: 12/07/2021","primary_completion_date":" 12/07/2021","study_txt":" Completion: 03/20/2022","study_completion_date":" 03/20/2022","last_update_posted":"2022-07-08"},{"id":"e042b558-d137-466c-b02c-21bbc895a34e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05151224","created_at":"2021-12-09T18:00:18.649Z","updated_at":"2024-07-02T16:36:19.667Z","phase":"","brief_title":"Circulating microRNA 21 Expression Level Before and After Neoadjuvant Systemic Therapy in Breast Carcinoma","source_id_and_acronym":"NCT05151224","lead_sponsor":"Ain Shams University","biomarkers":" HER-2 • BCL2 • MIR21","pipe":" | ","alterations":" HER-2 positive • miR-21 expression","tags":["HER-2 • BCL2 • MIR21"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • miR-21 expression"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 01/01/2024","study_completion_date":" 01/01/2024","last_update_posted":"2021-12-09"},{"id":"e1fdb15b-9af9-492f-9fbe-6e3f1ec86b89","acronym":"MindGAP-P","url":"https://clinicaltrials.gov/study/NCT04298398","created_at":"2021-01-18T20:51:07.708Z","updated_at":"2024-07-02T16:36:39.818Z","phase":"","brief_title":"Impact of Group Psychological Interventions on Extracellular Vesicles in People Who Had Cancer","source_id_and_acronym":"NCT04298398 - MindGAP-P","lead_sponsor":"Instituto Portugues de Oncologia, Francisco Gentil, Porto","biomarkers":" IFNG • IL6 • CEACAM5 • CXCL8 • IL10 • MIR21","pipe":"","alterations":" ","tags":["IFNG • IL6 • CEACAM5 • CXCL8 • IL10 • MIR21"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 09/01/2021","start_date":" 09/01/2021","primary_txt":" Primary completion: 09/01/2021","primary_completion_date":" 09/01/2021","study_txt":" Completion: 09/01/2021","study_completion_date":" 09/01/2021","last_update_posted":"2020-10-21"}]